{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:24:14Z","timestamp":1793255054488,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypercalcemic hyperparathyroidism has been associated with poor outcomes after kidney transplantation (KTx). However, the clinical implications of normocalcemic hyperparathyroidism after KTx are unclear. This retrospective cohort study attempted to identify these implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Normocalcemic recipients who underwent KTx between 2000 and 2016 without a history of parathyroidectomy were included in the study. Those who lost their graft within 1 year posttransplant were excluded. Normocalcemia was defined as total serum calcium levels of 8.5\u201310.5\u2009mg\/dL, while hyperparathyroidism was defined as when intact parathyroid hormone levels exceeded 80\u2009pg\/mL. The patients were divided into two groups based on the presence of hyperparathyroidism 1 year after KTx. The primary outcome was the risk of graft loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 892 consecutive patients, 493 did not have hyperparathyroidism (HPT-free group), and 399 had normocalcemic hyperparathyroidism (NC-HPT group). Ninety-five patients lost their grafts. Death-censored graft survival after KTx was significantly lower in the NC-HPT group than in the HPT-free group (96.7% vs. 99.6% after 5 years, respectively,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Cox hazard analysis revealed that normocalcemic hyperparathyroidism was an independent risk factor for graft loss (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002; hazard ratio, 1.94; 95% confidence interval, 1.27\u20132.98).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Normocalcemic hyperparathyroidism 1 year after KTx was an independent risk factor for death-censored graft loss. Early intervention of elevated parathyroid hormone levels may lead to better graft outcomes, even without overt hypercalcemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-022-02840-5","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:02:28Z","timestamp":1655406148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Manabu","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Tomosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ichimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuharu","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Watarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"2840_CR1","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"2840_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/oxfordjournals.ndt.a027843","volume":"13","author":"W Reinhardt","year":"1998","unstructured":"Reinhardt W, Bartelworth H, Jockenh\u00f6vel F, Schmidt-Gayk H, Witzke O, Wagner K, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13:436\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.transproceed.2015.12.120","volume":"48","author":"HH Lee","year":"2016","unstructured":"Lee HH, Kim AJ, Ro H, Jung JY, Chang JH, Chung W, et al. Sequential changes of vitamin D level and parathyroid hormone after kidney transplantation. Transplant Proc. 2016;48:897\u20139.","journal-title":"Transplant Proc"},{"key":"2840_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/TP.0000000000000583","volume":"99","author":"H Pihlstr\u00f8m","year":"2015","unstructured":"Pihlstr\u00f8m H, Dahle DO, Mj\u00f8en G, Pilz S, M\u00e4rz W, Abedini S, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015;99:351\u20139.","journal-title":"Transplantation."},{"key":"2840_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.surg.2017.12.010","volume":"163","author":"MJCLN Araujo","year":"2018","unstructured":"Araujo MJCLN, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018;163:1144\u201350.","journal-title":"Surgery."},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/SLA.0000000000001431","volume":"262","author":"I Lou","year":"2015","unstructured":"Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R, et al. How well does renal transplantation cure hyperparathyroidism? Ann Surg. 2015;262:653\u20139.","journal-title":"Ann Surg"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygcen.2007.11.003","volume":"156","author":"RV Talmage","year":"2008","unstructured":"Talmage RV, Mobley HT. Calcium homeostasis: reassessment of the actions of parathyroid hormone. Gen Comp Endocrinol. 2008;156:1\u20138.","journal-title":"Gen Comp Endocrinol"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.amjoto.2017.06.009","volume":"38","author":"JA Tang","year":"2017","unstructured":"Tang JA, Friedman J, Hwang MS, Salapatas AM, Bonzelaar LB, Friedman M. Parathyroidectomy for tertiary hyperparathyroidism: a systematic review. Am J Otolaryngol. 2017;38:630\u20135.","journal-title":"Am J Otolaryngol"},{"key":"2840_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247\u201388.","journal-title":"Ther Apher Dial"},{"key":"2840_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1399-0012.2007.00690.x","volume":"21","author":"OI Egbuna","year":"2007","unstructured":"Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transpl. 2007;21:558\u201366.","journal-title":"Clin Transpl"},{"key":"2840_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1399-0012.2010.01292.x","volume":"25","author":"J Moore","year":"2011","unstructured":"Moore J, Tomson CR, Tessa Savage M, Borrows R, Ferro CJ. Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clin Transpl. 2011;25:406\u201316.","journal-title":"Clin Transpl"},{"key":"2840_CR12","first-page":"564","volume-title":"Surgery of the thyroid and parathyroid glands","author":"Y Tominaga","year":"2020","unstructured":"Tominaga Y. Surgical Management of Secondary and Tertiary Hyperparathyroidism. In: Randolph G, editor. Surgery of the thyroid and parathyroid glands. 3rd ed. Philadelphia: Elsevier; 2020. p. 564\u201375.","edition":"3"},{"key":"2840_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40618-019-01075-w","volume":"42","author":"N Yalla","year":"2019","unstructured":"Yalla N, Bobba G, Guo G, Stankiewicz A, Ostlund R. Parathyroid hormone reference ranges in healthy individuals classified by vitamin d status. J Endocrinol Investig. 2019;42:1353\u201360.","journal-title":"J Endocrinol Investig"},{"key":"2840_CR14","first-page":"598","volume":"1","author":"Anonymous.","year":"1977","unstructured":"Anonymous. Correcting the calcium. Br Med J. 1977;1:598.","journal-title":"Br Med J"},{"key":"2840_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2840_CR16","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/j.1600-6143.2009.02671.x","volume":"9","author":"Y Iordanous","year":"2009","unstructured":"Iordanous Y, Seymour N, Young A, Johnson J, Iansavichus AV, Cuerden MS, et al. Recipient outcomes for expanded criteria living kidney donors: the disconnect between current evidence and practice. Am J Transplant. 2009;9:1558\u201373.","journal-title":"Am J Transplant"},{"key":"2840_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00423-017-1584-7","volume":"403","author":"J Liese","year":"2018","unstructured":"Liese J, Bottner N, B\u00fcttner S, Reinisch A, Woeste G, Wortmann M, et al. Influence of the recipient body mass index on the outcomes after kidney transplantation. Langenbeck's Arch Surg. 2018;403:73\u201382.","journal-title":"Langenbeck's Arch Surg"},{"key":"2840_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S2213-8587(16)30317-5","volume":"5","author":"WH Lim","year":"2017","unstructured":"Lim WH, Wong G, Pilmore HL, McDonald S, Chadban SJ. Long-term outcomes of kidney transplantation in people with type 2 diabetes a population cohort study. Lancet Diabetes Endocrinol. 2017;5:26\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2840_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1600-6143.2009.02985.x","volume":"10","author":"JM Gloor","year":"2010","unstructured":"Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant. 2010;10:582\u20139.","journal-title":"Am J Transplant"},{"key":"2840_CR20","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","volume":"393","author":"FG Scurt","year":"2019","unstructured":"Scurt FG, Ewert L, Mertens PR, Haller H, Schmidt BM, Chatzikyrkou C. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet. 2019;393:2059\u201372.","journal-title":"Lancet."},{"key":"2840_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.ajkd.2017.04.014","volume":"70","author":"B Merhi","year":"2017","unstructured":"Merhi B, Shireman T, Carpenter MA, Kusek JW, Jacques P, Pfeffer M, et al. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients an ancillary study of the FAVORIT trial cohort. Am J Kidney Dis. 2017;70:377\u201385.","journal-title":"Am J Kidney Dis"},{"key":"2840_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.tp.0000188135.04259.2e","volume":"81","author":"M Salvadori","year":"2006","unstructured":"Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche L, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation. 2006;81:202\u20136.","journal-title":"Transplantation."},{"key":"2840_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2840_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/1744-9987.12352","volume":"20","author":"Y Tominaga","year":"2016","unstructured":"Tominaga Y, Kakuta T, Yasunaga C, Makamura M, Kadokura Y, Tahara H. Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the parathyroid surgeons\u2019 society of Japan. Ther Apher Dial. 2016;20:6\u201311.","journal-title":"Ther Apher Dial"},{"key":"2840_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ctr.12341","volume":"28","author":"IH Bleskestad","year":"2014","unstructured":"Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, G\u00f8ransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transpl. 2014;28:479\u201386.","journal-title":"Clin Transpl"},{"key":"2840_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2215\/CJN.08680811","volume":"7","author":"C Nakano","year":"2012","unstructured":"Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012;7:810\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2840_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/jcm9030629","volume":"9","author":"M Simeoni","year":"2020","unstructured":"Simeoni M, Perna AF, Fuiano G. Secondary hyperparathyroidism and hypertension: an intriguing couple. J Clin Med. 2020;9:629.","journal-title":"J Clin Med"},{"key":"2840_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","volume":"55","author":"TF Marques","year":"2011","unstructured":"Marques TF, Vasconcelos R, Diniz E, R\u00eago D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol. 2011;55:314\u20137.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2840_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/EP15704.OR","volume":"22","author":"H \u0160iprov\u00e1","year":"2016","unstructured":"\u0160iprov\u00e1 H, Fry\u0161\u00e1k Z, Sou\u010dek M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract. 2016;22:294\u2013301.","journal-title":"Endocr Pract"},{"key":"2840_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","volume":"117","author":"KM Tordjman","year":"2004","unstructured":"Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117:861\u20133.","journal-title":"Am J Med"},{"key":"2840_CR31","doi-asserted-by":"publisher","first-page":"128352","DOI":"10.1155\/2012\/128352","volume":"2012","author":"LM Amaral","year":"2012","unstructured":"Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.","journal-title":"J Osteoporos"},{"key":"2840_CR32","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177:R297\u2013308.","journal-title":"Eur J Endocrinol"},{"key":"2840_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.surg.2019.05.094","volume":"167","author":"O Koubaity","year":"2020","unstructured":"Koubaity O, Mandry D, Nguyen-Thi P-L, Kobayashi T, Iwaki M, Honda Y, et al. Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery. 2020;167:149\u201354.","journal-title":"Surgery."},{"key":"2840_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12872-019-1093-4","volume":"19","author":"S Beysel","year":"2019","unstructured":"Beysel S, Caliskan M, Kizilgul M, Apaydin M, Kan S, Ozbek M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019;19:106.","journal-title":"BMC Cardiovasc Disord"},{"key":"2840_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.surg.2008.07.026","volume":"144","author":"JA Trunzo","year":"2008","unstructured":"Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery. 2008;144:915\u20139.","journal-title":"Surgery."},{"key":"2840_CR36","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0002-9610(99)00194-4","volume":"178","author":"C Yasunaga","year":"1999","unstructured":"Yasunaga C, Nakamoto M, Matsuo K, Nishihara G, Yoshida T, Goya T. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg. 1999;178:332\u20136.","journal-title":"Am J Surg"},{"key":"2840_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, et al. PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 2016;23:315\u201323.","journal-title":"Cell Metab"},{"key":"2840_CR38","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/ki.2014.215","volume":"86","author":"T Meir","year":"2014","unstructured":"Meir T, Durlacher K, Pan Z, Amir G, Richards WG, Silver J, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014;86:1106\u201315.","journal-title":"Kidney Int"},{"key":"2840_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584\u201392.","journal-title":"N Engl J Med"},{"key":"2840_CR40","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393\u2013408.","journal-title":"J Clin Invest"},{"key":"2840_CR41","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Bio Chem. 2014;289:9795\u2013810.","journal-title":"J Bio Chem"},{"key":"2840_CR42","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1172\/JCI83470","volume":"126","author":"J Rossaint","year":"2016","unstructured":"Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenst\u00e4dt HJ, Meersch M, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126:962\u201374.","journal-title":"J Clin Invest"},{"key":"2840_CR43","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985\u201396.","journal-title":"Kidney Int"},{"key":"2840_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/ijms22010408","volume":"22","author":"S Panizo","year":"2021","unstructured":"Panizo S, Mart\u00ednez-Arias L, Alonso-Montes C, Cannata P, Mart\u00edn-Carro B, Fern\u00e1ndez-Mart\u00edn JL, et al. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci. 2021;22:408.","journal-title":"Int J Mol Sci"},{"key":"2840_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","volume":"26","author":"S Sho","year":"2019","unstructured":"Sho S, Kuo EJ, Chen AC, Li N, Yeh MW, Livhits MJ. Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism. Ann Surg Oncol. 2019;26:539\u201346.","journal-title":"Ann Surg Oncol"},{"key":"2840_CR46","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1210\/jc.2013-1518","volume":"98","author":"E Koumakis","year":"2013","unstructured":"Koumakis E, Souberbielle J-C, Sarfati E, Meunier M, Maury E, Gallimard E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98:3213\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"2840_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","volume":"403","author":"E Traini","year":"2018","unstructured":"Traini E, Bellantone R, Tempera SE, Russo S, De Crea C, Lombardi CP, et al. Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbeck\u2019s Arch Surg. 2018;403:317\u201323.","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"2840_CR48","first-page":"475","volume":"83","author":"L Grimelius","year":"1976","unstructured":"Grimelius L, Ejerblad S, Johansson H. Parathyroid adenomas and glands in normocalcemic hyperparathyroidism. A light microscopic study. Am J Pathol. 1976;83:475\u201384.","journal-title":"Am J Pathol"},{"key":"2840_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/bjs.10739","volume":"105","author":"S Bannani","year":"2018","unstructured":"Bannani S, Christou N, Gu\u00e9rin C, Hamy A, Sebag F, Mathonnet M, et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg. 2018;105:223\u20139.","journal-title":"Br J Surg"},{"key":"2840_CR50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/TP.0b013e3181d62f1b","volume":"89","author":"JR Chapman","year":"2010","unstructured":"Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation. 2010;89:644\u20135.","journal-title":"Transplantation."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02840-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:04:02Z","timestamp":1655409842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02840-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Japanese Red Cross Nagoya Daini Hospital (approval number: 1409) and was conducted in accordance with the Declaration of Helsinki. The informed consent waiver was obtained from the Institutional Review Board of Japanese Red Cross Nagoya Daini Hospital. Details regarding the study and opt-out were provided in full on our institutional website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}